Figure 3

Treatment of EAE with ATROSAB improves histopathological alterations associated with the chronic phase of EAE. Mice were treated with either 20 mg/kg ATROSAB (B,E,H,K) or a corresponding control IgG (C,F,I,L) on days 1, 4, 8 and 12 of EAE, and sacrificed during the chronic phase of the disease on day 28 of EAE. (A) Analysis of demyelination by staining of spinal cord sections with LFB showed that ATROSAB significantly reduced spinal cord demyelination in mice not developing anti-drug antibodies (ADAs). (D) Axonal injury, as indicated by immunohistochemistry using an antibody against APP, was significantly reduced in the ATROSAB-treated group and was highly significant in treated mice which didn’t develop ADAs. Infiltration of CD3⁺ T cells (G) into the spinal cord was significantly reduced in ATROSAB treated mice which didn’t develop ADAs, but was significantly elevated in those that did. The presence of Mac-3⁺ activated microglia and macrophages (J) was not significantly altered between mice receiving either Con IgG or ATROSAB, although a significant elevation was seen in the sub-group which developed ADAs. ^*p < 0.05, ^**p < 0.01. n = 5 (con IgG) and 6 (ATROSAB). Scale bars C, I, L = 200 µm; F = 100 µm.